Ultrasound-guided radiofrequency ablation achieved disease control rates in trachea-adjacent papillary thyroid carcinoma that were comparable to tumors located farther from the airway, according to retrospective findings from Xuanwu Hospital. The study examined patients diagnosed with non-aggressive clinical-T1N0M0 papillary thyroid carcinoma to evaluate whether close proximity to the trachea compromised thermal ablation efficacy or heightened clinical risk. Researchers found that while proximity to the tracheal wall was linked to higher complication rates, every documented adverse event proved transient and resolved without leaving permanent sequelae.
The retrospective cohort included 423 patients presenting with a total of 563 clinical-T1N0M0 papillary thyroid carcinoma nodules treated with ultrasound-guided radiofrequency ablation between October 2020 and December 2023. All cases were confirmed as non-aggressive malignancies lacking distant metastasis or concurrent malignant diseases through ablation records and pre-procedural diagnostic imaging. Investigators categorized the nodules using a structural distance cutoff of two millimeters or less from the trachea to define the trachea-adjacent group, while nodules located beyond two millimeters formed the trachea-distant group.
Of the 563 treated nodules, 102 cases representing 18.1 percent were classified into the trachea-adjacent cohort, while 461 cases representing 81.9 percent formed the trachea-distant comparison group. Post-procedure clinical monitoring systematically evaluated rates of local recurrence, newly emerging lesions, regional lymph node metastasis, and therapeutic complications across both patient arms. Comparative analysis showed no statistically significant differences in complete nodule absorption or disease-free survival between the two cohorts across evaluated follow-up intervals, with all statistical comparisons yielding probability values greater than 0.05.
Across the entire study population, disease progression occurred in 10 patients, representing an overall progression rate of 2.36 percent during follow-up. This progression comprised eight cases of new lesions, two cases of lymph node metastasis, and zero instances of residual tumor tissue at primary ablation sites. The eight new lesions appeared at a mean detection time of 22.2 ± 1.1 months post-treatment.
After an extended mean follow-up of 37.6 ± 3.5 months, surveillance detected no additional new lesions or regional nodal spread. Subgroup analysis specifically documented zero cases of lymph node metastasis within the trachea-adjacent group throughout the monitoring period. Overall comparative metrics confirmed that the trachea-adjacent and trachea-distant cohorts exhibited comparable outcomes for both complete absorption rate and disease progression rate, with all statistical tests demonstrating p values exceeding 0.05.
Safety assessments identified procedural complications in 15 of the 423 treated patients, establishing an overall complication rate of 3.5 percent. Complications occurred more frequently in the trachea-adjacent cohort, which recorded 11 cases compared to four cases in the trachea-distant group. This difference between the two cohorts was statistically significant, with a p value below 0.05, demonstrating an increased procedural risk when treating nodules located within two millimeters of the tracheal cartilage.
All recorded complications occurred within the initial three months following radiofrequency ablation and subsequently resolved in full without permanent physical impairment. Multivariate logistic regression analysis identified two independent risk factors associated with procedural complications: nodule localization in the dorsal region of the thyroid gland and the physical extent of contact between the tumor lesion and the adjacent tracheal boundary.
The investigators concluded that ultrasound-guided radiofrequency ablation provides an effective and safe approach for treating clinical-T1N0M0 papillary thyroid carcinoma adjacent to the trachea. The ablation technique achieved complete tissue absorption and disease-free survival comparable to trachea-distant tumors, while avoiding local persistence and lymph node metastasis in proximity cases. The authors noted that when supported by precise preoperative evaluation and careful operative technique, radiofrequency ablation remains a sound therapeutic option despite transient complication risks.
Subject of Research: Efficacy and safety of radiofrequency ablation for trachea-adjacent papillary thyroid carcinoma
Article Title: The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study
Article References: Lv, Z., Yang, J., Wang, Y., Chang, Y., Yang, X., Jia, X., & Leng, Z. (2026). The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study. BMC Cancer. https://doi.org/10.1186/s12885-026-17372-6
Image Credits: AI Generated
DOI: 10.1186/s12885-026-17372-6
Keywords: radiofrequency ablation, papillary thyroid carcinoma, cT1N0M0, trachea-adjacent lesions, ultrasound-guided RFA, thyroid cancer, disease-free survival, complete absorption rate, lymph node metastasis, minimally invasive surgery, disease progression, postoperative complications, thyroid dorsal region, tracheal contact, re-ablation, Xuanwu Hospital, retrospective cohort
News Source: Nathaniel Bowman. (November 18, 2026). Radiofrequency Ablation Proves Effective for Trachea-Adjacent Thyroid Carcinoma in Clinical Study. Scienmag.



